Mounjaro — yes or no? What the evidence and your prescriber decide

What the trial data says about who tends to do well on Mounjaro

The SURMOUNT programme is the largest body of evidence for tirzepatide in weight management. SURMOUNT-1, published in the New England Journal of Medicine, followed 2,539 adults with obesity over 72 weeks. At the highest dose, average body-weight reduction reached around 20–21%, a figure that shifted the conversation about what weight-management medicine could achieve. The key word is average: some participants lost considerably more, others less, and a small number did not respond meaningfully. That spread is exactly why trial data alone cannot answer a personal yes-or-no.

The SURMOUNT-5 head-to-head trial, also published in 2025, compared tirzepatide directly with semaglutide 2.4 mg over 72 weeks in adults without diabetes. Tirzepatide produced greater average weight reduction. That result matters when you are comparing your options, though it does not mean semaglutide is the wrong choice for everyone, tolerability, medical history and personal preference all factor in. If you want to explore how the two compare, our weight-loss treatments overview sets out the differences clearly.

The practical takeaway from the evidence: tirzepatide works well on average, works best alongside reduced-calorie eating and regular activity, and works differently in different people. A prescriber's job is to map your individual profile onto that average.

The eligibility criteria the evidence shaped, and where they sit today

NICE assessed all of this evidence before recommending tirzepatide in December 2024 (TA1026, updated September 2025). The NICE recommendations set the NHS threshold at a BMI of 35 or above plus at least one qualifying weight-related condition, high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease or type 2 diabetes. For South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds the BMI threshold is 2.5 kg/m² lower throughout.

Private prescribing follows the licensed indications in the SmPC rather than NICE's NHS-access thresholds. The licence covers adults with a BMI of 30 or above, or 27 or above with at least one weight-related condition. So if your BMI sits between 30 and 34.9 with a relevant health condition, a private prescriber can assess you where an NHS GP operating under NICE guidance currently cannot. You can read more about how NHS and private routes differ on our Mounjaro without a GP referral page.

One practical check you can do in under a minute: the NHS BMI calculator gives you your number instantly. It will not tell you whether Mounjaro is suitable (only a prescriber can do that) but knowing your BMI before you start a consultation means you spend that time on the things that actually need a clinical eye.

The medical questions a prescriber asks before saying yes

Eligibility criteria open the door; they do not walk you through it. A prescriber reviewing a Mounjaro consultation is also looking at what is not on the checklist. A personal or family history of medullary thyroid carcinoma or MEN2 syndrome rules the medicine out. A history of pancreatitis needs careful discussion. Certain gastrointestinal conditions require assessment. The prescriber checks current medications for interactions, reviews blood-pressure and cardiovascular history, and considers whether any other condition might shift the risk-benefit balance.

Mounjaro is not recommended during pregnancy, breastfeeding, or if you are actively trying to conceive. It is not licensed for anyone under 18. Women taking oral contraceptives need to know that tirzepatide can reduce pill absorption in the first four weeks of treatment and after each dose increase, a non-oral method of contraception should be used during those windows. That is a detail that gets missed when prescribing is rushed. Our clinical team covers it as a matter of course. If you have questions about how tirzepatide interacts with other health conditions, the Mounjaro information page goes into more depth, and our clinical team is available to discuss specifics.

There is also the question of what Mounjaro is not. It is not insulin, a common point of confusion worth clearing up directly on our is Mounjaro insulin page. It does not work overnight. And it is not a standalone fix, the evidence repeatedly shows the best results come alongside dietary changes and activity, not instead of them. People also sometimes ask about unexpected physical changes during treatment, including how Mounjaro can affect the eyes, and that is worth reading about before you begin.

When the answer is more likely to be yes (and what comes next

The clearest candidates for a yes are adults who meet the BMI and comorbidity criteria, have no contraindications, have tried lifestyle changes without sufficient effect, and understand that the medicine supports) rather than replaces, those changes. The NICE committee, drawing on SURMOUNT data, concluded that tirzepatide offers meaningful clinical value for this group. The Black Triangle status means the MHRA continues to monitor real-world data; any prescriber worth consulting stays on top of those updates.

A no is also a genuine clinical outcome. If contraindications are present, if a different medicine suits your profile better, or if the evidence does not support treatment at this point, a prescriber at a rigorous service will say so. It is worth knowing that a Mounjaro consultation that results in a no is still a consultation that gave you a clear answer from a qualified clinician.

Side effects are part of the yes-or-no conversation too. The most common are gastrointestinal (nausea, loose stools, constipation, indigestion) typically most noticeable after starting or after a dose increase, and often settling within a couple of weeks. Serious effects are less common but real: the MHRA flagged acute pancreatitis as an infrequent but potentially serious risk in a January 2026 Drug Safety Update. Severe, persistent stomach pain that radiates to the back warrants urgent medical attention.

On cost: Mounjaro is a private prescription medicine and the price has shifted since Eli Lilly adjusted UK list prices in September 2025. Our Mounjaro prices page explains the current context clearly. If clinical assessment confirms suitability and you decide to go ahead, speaking to our prescribers is the logical next step, start your free consultation here and a GPhC-registered Independent Prescriber will review your answers the same day.